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Abstract
The molecular mechanisms for the dissemination and metastasis of gastrointestinal stromal tumours (GIST) are incompletely understood. The
purpose of the study was to investigate the clinical relevance of integrin alpha 4 (ITGA4) expression in GIST. GIST transcriptomes were first
compared with transcriptomes of other types of cancer and histologically normal gastrointestinal tract tissue in the MediSapiens in silico data-
base. ITGA4 was identified as an unusually highly expressed gene in GIST. Therefore, the effects of ITGA4 knock-down and selective integrin
alpha 4 beta 1 (VLA-4) inhibitors on tumour cell proliferation and invasion were investigated in three GIST cell lines. In addition, the prognostic
role of ITGA4 expression in cancer cells was investigated in a series of 147 GIST patients with immunohistochemistry. Inhibition of ITGA4-
related signalling decreased GIST cell invasion in all investigated GIST cell lines. ITGA4 protein was expressed in 62 (42.2%) of the 147 GISTs
examined, and expression was significantly associated with distant metastases during the course of the disease and several adverse prognostic
features. Patients whose GIST expressed strongly ITGA4 had unfavourable GIST-specific survival and overall survival compared to patients with
low or no ITGA4 expression. Taken together, ITGA4 is an important integrin in the molecular pathogenesis of GIST and may influence their clini-
cal behaviour.
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Introduction
GISTs are one of the most common types of soft-tissue sarcoma.
Gain of function mutations in KIT (encodes the KIT receptor tyrosine
kinase) is major molecular drivers in GISTs [1]. Approximately 75%
of GISTs harbour mutated KIT [2] and one-third of GISTs that lack
KIT mutation contain an activating mutation in the platelet-derived
growth factor receptor a (PDGFRA) gene [3]. About 20% of GISTs
are metastatic at the time of the diagnosis [4]. Metastases occur most
often in the liver and other intra-abdominal sites, whereas metastases
outside of the abdomen are uncommon [5–7]. Imatinib mesylate is
the standard first-line therapy for patients with inoperable or
metastatic GIST [8] and the standard adjuvant therapy after surgery
for patients with a high estimated risk for recurrence [9].
Although KIT and PDGFRA mutations are likely of key importance
in the molecular pathogenesis of GISTs, identical single KIT or
PDGFRA mutations may be associated with widely different tumour
mitotic counts and GIST patient survival outcome [2]. Such findings
suggest that aberrations in several other genes may be crucially
important in determining the propensity of GIST cells to proliferate,
invade and to give rise to metastases.
Relatively little is known about the relevance of integrins in the
molecular pathogenesis and clinical behaviour of GISTs. Integrins
have multiple roles in the cell signalling and in the regulation of cell
growth, division, survival, differentiation, migration and apoptosis
[10]. Integrin activity may change the polarity of migrating cells and
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the assembly of the extracellular matrix that may influence cancer
metastasis [11]. Integrin-targeting drugs are under clinical investiga-
tion for several diseases including cancer [12, 13], and many of this
target the RGD-binding integrins [12]. Besides cell migration and
invasion, integrins may also control cell proliferation [13]. Adhesion-
dependent control of cell proliferation may be deregulated in cancer,
and integrins regulate the growth of some cancers [14, 15]. Increased
expression of avb3, avb5, a5b1, a6b4, a4b1 and avb6 integrins has
been linked with cancer progression [12].
The ITGA4 family of integrins mediate cell–cell adhesions that are
crucial especially to the immune function [16]. The a4 peptide
(CD49d) associates with either the b1 chain (CD29) or the b7 chain
forming a4b1 (very late antigen-4, VLA-4) and a4b7 (lymphocyte
Peyer patch adhesion molecule) integrins, respectively. Alpha 4 inte-
grins are involved in haematopoiesis, myogenesis, and cardiac and
placental development [17–19]. The alpha 4 integrins are involved
also in the surveillance, inflammation and pathogenesis of cardiovas-
cular diseases [20]. a4b1 binds to the vascular cell adhesion mole-
cule-1 (VCAM-1) that is expressed on the surface of endothelial and
stromal cells and to fibronectin in the extracellular matrix, whereas
a4b7 binds to the mucosal vascular addressin cell adhesion mole-
cule-1 (MAd-CAM-1) [11]. Natalizumab, a humanized monoclonal
antibody that targets ITGA4 has been approved by the U.S. Food and
Drug Administration (FDA) for the treatment of multiple sclerosis and
Crohn’s disease [21, 22].
The role of ITGA4 is unknown in GISTs. In this study, we report
that ITGA4 is often expressed strongly in GISTs compared to many
other cancers and histopathologically normal human tissues, sug-
gesting a molecular pathologic role for ITGA4 in GIST. We found fur-
ther that high GIST ITGA4 expression in the tumour cells is
associated with unfavourable prognosis of patients and undertook
functional studies to investigate whether inhibition of ITGA4 with
siRNA or two VLA-4-specific inhibitors prevents invasion of GIST
cells. As ITGA4 can be targeted with monoclonal antibodies such as
natalizumab, and VLA-4-specific inhibitors such as BIO1211 and
BIO5192, these findings suggest that ITGA4 may be a potential thera-
peutic target in GIST.
Materials and methods
Patients
ITGA4 protein expression was determined in 173 soft-tissue sarcomas
consisting of eight different histopathological types. Formalin-fixed
paraffin-embedded (FFPE) tissue samples were selected at random and
collected from the archives of the Department of Pathology, Helsinki
University Hospital. We selected at random 13 GISTs, 29 leiomyosarco-
mas, eight synovial sarcomas and nine undifferentiated pleomorphic
sarcomas from these 173 sarcomas for the quantitative PCR (qPCR)
analysis of tumour ITGA4 mRNA content.
The associations between tumour ITGA4 expression, patient features,
and GIST clinical and histopathological parameters were investigated
from another series that consisted of 288 patients diagnosed with KIT-
positive GIST in western Sweden from 1983 through 2000 [6, 23]. The
characteristics of the patients and the GISTs in this series are described
in detail elsewhere [6]. These patients had undergone surgery for GIST,
and none received imatinib or other tyrosine kinase inhibitors as adju-
vant systemic treatment for GIST after surgery. GIST tissue was avail-
able for the original tissue microarray (TMA) block from 241 (83.7%) of
the 288 patients [24], of whom we included in this study, all 147
(61.0%) patients whose gender, tumour diameter, tumour site in the
gastrointestinal tract, and follow-up data were available, and whose
GIST diagnosis had been verified at a histopathological review. The
stratification for the risk of GIST recurrence was performed according
to the U.S. National Institutes of Health (NIH) criteria [25]. Institutional
review boards of the Helsinki University Hospital and the Gothenburg
University approved the study.
Outlier gene expression analysis
Genes that are highly expressed in GIST in comparison with histologi-
cally normal gastrointestinal tract tissue samples were identified and
ranked using the gene tissue index (GTI) outlier statistics as described
elsewhere [26]. Cancer and normal tissue mRNA expression data were
extracted from the MediSapiens in silico database that consists of tran-
scriptomes of 17,330 human genes across 9783 human tissue samples
and 175 histologically different tissue types (available at ist.medisapi-
ens.com) [27]. The analysis of ITGA4 mRNA expression in the database
was based on six GISTs and 34 histologically normal gastrointestinal
tract tissue samples.
Immunohistochemistry
For the construction of the TMA, representative areas consisting of
tumour were identified from each FFPE tissue block on H&E-stained tis-
sue sections, and two 0.7 mm (the sarcoma series) or one 0.6 mm
diameter (the western Sweden series) tumour tissue biopsies were sub-
sequently taken. The histological features of the tissue selected for the
western Sweden TMA were assessed by a pathologist, and the validity
of the tissue was confirmed by requiring positive staining for KIT at
immunohistochemical evaluation of the TMA.
ITGA4 protein expression was evaluated from 5-lm TMA sections
using immunohistochemistry. The TMA slides were deparaffinized in
xylene and hydrated in a graded series of alcohol. Endogenous peroxide
activity was blocked with hydrogen peroxide incubation. Antigen retrieval
for ITGA4 was carried out in sodium citrate (10 mmol/l, pH 6.0) in an
autoclave (at 120°C for 2 min.). The primary antibody was a polyclonal
rabbit ITGA4 antibody (dilution 1:100; A9385; LifeSpan BioSciences, Seat-
tle, WA, USA), which was diluted in a PowerVision pre-antibody blocking
solution and incubated for 30 min. on the slides at room temperature. Pri-
mary antibody binding was detected using a BrightVision+ Histostaining
kit (Immunologic BV, Duiven, The Netherlands) and 3,30-diaminobenzidine
(ImmPACT™ DAB; Vector Laboratories, Burlingame, CA, USA) following
the manufacturer’s instructions. The slides were counterstained with
Mayer’s haematoxylin. ITGA4 showed uniform staining within 13 large
GIST tissue sections, and, therefore, tumour ITGA4 expression was cate-
gorized as negative, low or high based on the staining intensity (Fig. 1B).
Only cancer cell ITGA4 expression was scored, but the endothelial cells
and leucocytes were also observed to stain positive for ITGA4. The
immunostainings were assessed blinded without knowledge of the clinical
or histopathological data.
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qPCR assay
RNA was extracted from the FFPE tissue sections using a High Pure
RNA Paraffin kit (Roche Diagnostics GmbH, Mannheim, Germany) and
from the GIST cell lines using a High Pure RNA Isolation Kit (Roche
Diagnostics GmbH). The mRNA was reverse transcribed to cDNA with a
SuperScript VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
ITGA4 mRNA expression of 13 GISTs, 29 leiomyosarcomas, eight
synovial sarcomas and nine undifferentiated pleomorphic sarcomas
was quantitated with real-time qPCR using hydrolysis probes (i.e.
hybridization probes labelled with a reporter dye and a quenching dye)
in a LightCycler 480 instrument (Roche Diagnostics GmbH). cDNA was
amplified in a 20 ll PCR mixture using LightCycler 480 Probes Master
reagents (Roche Diagnostics GmbH) and a fluorescein-labelled locked
nucleic acid (LNA) hydrolysis probe 13 or an LNA hydrolysis probe
G6PD from a Universal ProbeLibrary Set (Roche Diagnostics GmbH).
The PCR mixture contained 19 PCR buffer, 100 nmol/l of probe and
200 nmol/l of each primer specific for the ITGA4-coding region (for-
ward: 50-AGGAAGTTCCAGGTTACATTGTTT-30; reverse: 50-TTAGAAGAGA
AATAGAATCTTGGTGGA-30) or for G6PD as the reference DNA (forward:
50-GAGCCAGATGCACTTCGTG-30; reverse: 50-GGGCTTCTCCAGCTCAATC-30).
Fig. 1 (A) A box–whisker plot showing the relative ITGA4 mRNA expression in histopathologically normal gastric, small intestine and colorectal tis-
sue (green boxes) and in different types of cancer (red boxes). The number of samples studied is indicated in the brackets. (B) Examples of nega-
tive, low and high ITGA4 expression in GIST tissue samples (magnification 9200). (C) Association between ITGA4 protein expression at
immunohistochemistry and the normalized ITGA4 mRNA expression (P < 0.001) determined from the same samples with qPCR. Panel A is modified
from IST OnlineTM (ist.medisapiens.com).
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The ProbeFinder program at the Assay Design Center of Universal Pro-
beLibrary (www.universalprobelibrary.com; Roche Diagnostics GmbH)
was used for the design of the primers and the probes. The cycling
parameters consisted of an initial denaturation at 95°C for 10 min., fol-
lowed by 60 cycles with denaturation at 95°C for 15 sec., annealing at
60°C for 45 sec. and elongation at 72°C for 45 sec. The results were
analysed using the Basic Relative Quantification method (Roche Diag-
nostics GmbH).
Cell lines
GIST882 and GIST48 cell lines were a kind gift from Dr. Jonathan A.
Fletcher (Harvard Medical School, Boston, MA, USA). GIST-T1 cell line
was purchased from Cosmo Bio (Tokyo, Japan). GIST882 is a primary
human GIST cell line with a homozygous missense mutation in KIT
exon 13, encoding a p.K642E mutant KIT oncoprotein [28]. GIST48 is a
GIST cell line that progressed after an initial response to imatinib and
harbours a primary KIT exon 11 p.V560D missense mutation and a sec-
ondary exon 17 missense mutation p.D820A [29]. The GIST-T1 cell line
was established from a metastatic pleural tumour from a primary gas-
tric GIST. GIST-T1 is a KIT exon 11 mutant cell line that has a heterozy-
gous in-frame deletion of 57 bases [30]. The authenticity of the
GIST882, GIST48 and GIST-T1 cell lines was confirmed with DNA
sequencing. The cells were cultured in a humidified 5% CO2 atmosphere
at 37°C. GIST882 and GIST48 cells were cultured in the RPMI 1640
medium (GIBCO, Carlsbad, CA, USA), supplemented with 20% foetal
bovine serum with 2% penicillin/streptomycin (GIBCO), and GIST-T1
cells were cultured in a DMEM medium (Lonza, Walkersville, MD, USA)
supplemented with 10% foetal bovine serum with 2% penicillin/strepto-
mycin (GIBCO).
VLA-4 inhibitors
BIO1211 and BIO5192, both integrin a4b1 (VLA-4)-specific inhibitors,
were purchased from Tocris Bioscience (Bristol, UK). BIO1211 was
reconstituted in PBS and BIO5192 was in DMSO.
Cell proliferation and invasion assays
GIST cell proliferation was studied with the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Roche Diagnostics, Indi-
anapolis, IN, USA). For the assay, 15,000 GIST882 cells, 20,000 GIST48
cells and 5000 GIST-T1 cells were plated in 96-well plates. The analyses
were performed three times, and eight replicate wells were assessed at
each time-point. The effect of siRNAs for cell proliferation was analysed
at 0, 24, 48, 72 and 98 hrs, and the effect of VLA-4 inhibitors was anal-
ysed at 72 hrs using 10 different concentrations. After adding 10 ll of
the MTT reagent into each well and incubation for 4 hrs at 37°C, a sol-
ubilization solution was added to dissolve the formazan crystals over-
night at 37°C. The 96-well plates were read with a Multiscan EX
Microplate photometer (Thermo Scientific, Rockford, IL, USA) at the
wavelength of 540 nm.
For the cell invasion assay, 50 ll of 2.5 mg/ml matrigel containing
5 lg/ml fibronectin was placed into the upper chamber of a 24-well
transwell (Corning™ Falcon™ Cell Culture Inserts, 8.0 lm pore size;
Fisher Scientific). Six hundred microlitre of the RPMI 1640 medium
supplemented with 20% foetal bovine serum and 2% penicillin/strepto-
mycin was added to the lower chamber of the transwell. GIST882 cells
were plated at the density of 20,000 cells/well, GIST48 cells at the den-
sity of 30,000 cells/well and GIST-T1 cells at the density of 10,000
cells/well in a medium without serum to the upper chamber of the
transwell. GIST48 and GIST882 cells were incubated for 24 hrs and
GIST-T1 cells for 96 hrs. Cell invasion was measured in three separate
experiments by counting the cells within 10 photographed fields of the
microscope (Leica CTR6000; Leica microsystems, Bannockburn, IL,
USA; magnification 9200). The number of invaded cells was expressed
as the average number of invaded cells per one microscope field.
siRNA transfections
The Lipofectamine 2000 Transfection Reagent (Invitrogen) was used for
the GIST cell siRNA transfections. The cells were first serum starved for
6 hrs in an Opti-MEM reduced serum medium (GIBCO). Following this,
transfections were performed according to the manufacturer’s instruc-
tions adding 5 pmol/l of siRNA onto the GIST882 and GIST48 cells and
10 pmol/l of siRNA onto the GIST-T1 cells. The transfections were per-
formed with an ON-TARGET plus Human KIT siRNA and an ON-TARGET
plus Human ITGA4 siRNA, which are pools of target-specific siRNAs
(Thermo Scientific Dharmacon, Rockford, IL, USA). The ON-TARGET
plus Non-Targeting Pool (Thermo Scientific Dharmacon) was used as
the negative control.
Western blotting
Cultured GIST cell lines were rinsed in PBS (Lonza) and scraped on ice
into a RIPA lysis buffer (Pierce Biotechnology, Rockford, IL, USA) con-
taining a Pierce Protease and Phosphatase Inhibitor Tablet (Thermo
Fisher Scientific Inc.), followed by sonication. The protein concentra-
tions were measured using a Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific Inc.). Ten microgram of protein was separated using
gel electrophoresis and blotted onto an Immobilon-P Transfer Mem-
brane (Millipore, Billerica, MA, USA). The primary antibodies were a
monoclonal rabbit anti-ITGA4 antibody (dilution 1:1000; clone D2E1;
Cell Signaling Technology, Danvers, MA, USA), a polyclonal rabbit anti-
c-KIT antibody (dilution 1:10,000; A4502; Agilent Technologies Dako,
Glostrup, Denmark), a polyclonal rabbit anti-Phospho-c-KIT (Tyr703)
antibody (dilution 1:10,000; 3391; Cell Signaling Technology), a
polyclonal rabbit b-Actin (dilution 1:10,000; Bethyl Laboratories, Mont-
gomery, TX, USA) and a peroxidase-conjugated AffiniPure Goat Anti-
Rabbit antibody was used as the secondary antibody (dilution 1:10,000;
Jackson Immuno Research, West Grove, PA, USA). Blot immunostains
were treated with a SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific Inc.), exposed to an X-ray film, and the films
were developed with a Kodak Medical X-ray Processor 102 (Eastman
Kodak; Rochester, NY, USA).
Statistical analysis
The frequency tables were analysed with the chi-squared test. Continu-
ous parameters were compared with the Mann–Whitney test or the
Kruskal–Wallis test. Cumulative survival was estimated with the Kaplan–
Meier method and the log-rank test. Overall survival was calculated
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from the date of the GIST diagnosis to the date of death, censoring
patients who were alive on the last date of follow-up. GIST-specific sur-
vival was computed from the date of the diagnosis to death deemed to
result from GIST, censoring patients who died from another cause on
the date of death and patients who were alive on the last date of follow-
up. All P-values are two-sided. The inter-rater agreement in immunohis-
tochemical scoring of ITGA4 between two independent raters (O.P.P.
and O.T.), and the intra-rater agreement were measured by computing
Cohen’s kappa coefficient. The statistical calculations were carried out
using an SPSS Statistics package v. 22.0 (IBM, Armonk, NY, USA).
Results
ITGA4 expression in cancer
ITGA4 mRNA expression was high in GISTs as compared with other
types of cancer and healthy gastrointestinal tract tissues available in
the MediSapiens database (IST Online™ at ist.medisapiens.com)
based on the GTI outlier analysis (Fig. 1A). Only GISTs and haemato-
logical malignancies expressed high levels of ITGA4 mRNA. For com-
parison, in a similar analysis, KIT mRNA turned out to be highly
expressed in GISTs as compared with the reference group (Fig. S1).
Expression of the ITGA4 protein was next investigated with
immunohistochemistry on a sarcoma TMA. ITGA4 was detected in 44
(78.6%) of the 56 GISTs examined, of which expression was classi-
fied as high in 16 (28.6%) and low in 28 (50.0%; Fig. 1B and
Table 1). ITGA4 expression (either low or high) was detected also in
other types of sarcomas, but much less frequently than in GISTs (61
[52.1%] out of 117, P = 0.0009). Similarly, high tumour ITGA4
expression was also more frequent in GISTs in comparison with other
sarcomas examined (16 [28.6%] out 56 versus 16 [13.7%] out of
117, P = 0.018). Besides GIST, strong ITGA4 expression was present
frequently in four (10.5%) of 38 undifferentiated pleomorphic sarco-
mas, in eight (26.7%) of 30 leiomyosarcomas and four (23.5%) of 17
synovial sarcomas.
The specificity of ITGA4 immunostaining was examined by com-
paring ITGA4 protein expression at immunohistochemistry with
ITGA4 mRNA expression measured with qPCR. Thirteen randomly
selected GISTs, 29 leiomyosarcomas, eight synovial sarcomas and
nine undifferentiated pleomorphic sarcomas were included in the
analysis. Of these 59 tumours, six GISTs, five leiomyosarcomas and
one synovial sarcoma showed high ITGA4 expression at immunohis-
tochemistry. Weak ITGA4 expression was present in five GISTs, 16
leiomyosarcomas, two synovial sarcomas and three undifferentiated
pleomorphic sarcomas. The median ITGA4 gene to control G6PD
gene mRNA expression ratio in GIST was 6.7 (range = 0.18–15.94,
P = 0.002) and in other tumours 2.1 (range = 0.10–6.23). ITGA4
protein expression at immunohistochemistry correlated significantly
with ITGA4 mRNA expression at qPCR lending support to the speci-
ficity of the immunohistochemical staining (P < 0.001, Fig. 1C).
Clinical relevance
The clinical relevance of GIST ITGA4 protein expression was investi-
gated in the western Sweden population-based GIST patient series.
As the current study is based on a subset of the patients in the west-
ern Sweden series, we compared age at the time of the diagnosis,
gender, the NIH risk classification distribution, and the main GIST
prognostic features in the current subset and the entire western Swe-
den series. We found no significant differences between the current
subset and the entire series in any of these parameters, suggesting
that no major imbalance had occurred in patient selection (Table S1).
The median age of the patients at the time of GIST diagnosis
was 70 years (range, 30–92 years), and 74 (50.3%) of the
Table 1 ITGA4 expression in 173 human sarcomas
Tumour type No. of tumours
ITGA4 expression
Negative n (%) Low n (%) High n (%)
Gastrointestinal stromal tumour (GIST) 56 12 (21.4) 28 (50.0) 16 (28.6)
Angiosarcoma 11 4 (36.4) 7 (63.6) 0 (0.0)
Chondrosarcoma 8 6 (75.0) 2 (25.0) 0 (0.0)
Fibrosarcoma 5 5 (100.0) 0 (0.0) 0 (0.0)
Undifferentiated pleomorphic sarcoma 38 21 (55.3) 13 (34.2) 4 (10.5)
Leiomyosarcoma 30 7 (23.3) 15 (50.0) 8 (26.7)
Liposarcoma 8 4 (50.0) 4 (50.0) 0 (0.0)
Synovial sarcoma 17 9 (52.9) 4 (23.5) 4 (23.5)
Total 173 68 (39.3) 73 (42.2) 32 (18.5)
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N = 85 n (%)
Low
N = 48 n (%)
High
N = 14 n (%)
Gender
Female 46 (54.1) 21 (43.8) 6 (42.9) 0.448
Male 39 (45.9) 27 (56.2) 8 (57.1)
Location
Gastric 37 (43.5) 31 (64.6) 10 (71.4) 0.023
Non-gastric 48 (56.5) 17 (35.4) 4 (28.6)
NIH risk stratification
Low/intermediate 62 (43.5) 28 (73.7) 4 (36.4) 0.009
High 16 (56.5) 10 (26.3) 7 (63.6)
N.A.* 7 10 3
Histological type
Spindle cell 63 (78.8) 30 (68.2) 8 (57.1) 0.160
Other 17 (21.3) 14 (31.8) 6 (42.9)
N.A. 5 4 0
Distant metastases during the course of disease
Absent 73 (85.9) 22 (68.8) 6 (42.9) 0.001
Present 12 (14.1) 15 (31.3) 8 (57.1)
Tumour necrosis
Absent 47 (73.4) 22 (71.0) 2 (18.2) 0.001
Present 17 (26.6) 9 (29.0) 9 (81.8)
N.A. 21 17 3
Mitotic count (per 50 HPFs)
0–5 70 (85.4) 31 (66.0) 5 (35.7) <0.001
>5 12 (14.6) 16 (34.0) 9 (64.3)
N.A. 3 1 0
Median age—years (range) 71 (30–92) 68 (44–86) 68 (50–85) 0.191
Median tumour size—cm (range) 5.0 (0.5–33.0) 6.0 (1.5–30.0) 9.0 (1.0–30.0) 0.153
Tumour size class-cm
<2 15 (17.6) 6 (12.5) 1 (7.1) 0.501
>2 70 (82.4.) 42 (87.5) 13 (92.9)
N.A., not available; NIH, the National Institutes of Health; HPF, high-power field of the microscope.
*GISTs with metastases at the time of the diagnosis (n = 20).
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patients were male. GIST ITGA4 expression was present in 62
(42.2%) of the 147 GISTs. High expression was present in 14
(9.5%) GISTs, low expression in 48 (32.7%), and 85 (57.8%)
tumours were negative in immunostaining for ITGA4. When GISTs
with negative, low or high ITGA4 expression were compared,
ITGA4 expression was associated with a tumour location in the
stomach, the high NIH risk stratification group for recurrence,
presence of tumour necrosis, and a high tumour mitotic count (all
P-values <0.05; Table 2). GIST ITGA4 expression was associated
also with presence of distant metastases during the course of the
disease (P = 0.001). The majority of the 20 GISTs with metastases
present at the time of GIST diagnosis were ITGA4-positive (nega-
tive n = 7, weak n = 10, high n = 3), although this association
between GIST ITGA4 expression and metastases was not signifi-
cant (P = 0.084). GIST ITGA4 expression was not significantly
associated with tumour size when size was tested as a continuous
variable (Table 2). Similarly, when small GISTs (<2 cm in diame-
ter) were compared with larger GISTs, there was no difference in
GIST ITGA4 expression between the groups. When the patients
with GIST with either negative or low ITGA4 expression were com-
bined and compared to those with high ITGA4 expression, the
results remained similar (Table S2).
When the inter-rater agreement in immunohistochemical scoring
of GIST ITGA4 expression was compared between two independent
raters in the western Sweden series, the agreement turned out to be
good (kappa coefficient 0.75, 95% CI: 0.65–0.85). The intra-rater
agreement in the western Sweden series was almost perfect (kappa
coefficient 0.88, 95% CI: 0.84–0.92).
The median follow-up time of the patients alive was 7.6 years
(range, 1–20 years). Seventy-five (51.0%) patients died during the
follow-up. GIST ITGA4 expression was significantly associated with
poor overall survival and GIST-specific survival (Fig. 2).
Cell proliferation and invasion analyses
As GIST ITGA4 expression was associated with several clinical high-
risk features and unfavourable survival, the function of ITGA4 was
further investigated in three GIST cell lines that were all KIT-positive
at immunohistochemistry. ITGA4 protein expression was present in
all three cell lines (Fig. 3). When ITGA4 and KIT were depleted in the
cell lines with the respective siRNAs, KIT interference with siRNA
reduced significantly the proliferation rate of all cell lines during a 4-
day follow-up period (all P-values <0.001). ITGA4 RNA knock-down
had no effect on the proliferation rate of the cell lines (all P-values
>0.05; Fig. 4). VLA-4 inhibition by BIO1211 and BIO5192 had little
effect on cell proliferation (Fig. 5).
The effect of ITGA4 down-regulation for GIST cell invasion was
evaluated in a matrigel-coated transwell system in the presence of
fibronectin in three parallel experiments. The number of invaded cells
decreased in the GIST882, GIST48 and the GIST-T1 cell lines after
ITGA4 siRNA transfection as compared with the control siRNAs
(GIST882, mean = 3.4, standard error [S.E.] = 1.6 versus control,
mean = 29.7, S.E. = 8.2; P = 0.014; GIST48, mean = 8.3, S.E. =
2.9 versus control, mean = 23.2, S.E. = 4.5, P = 0.016; and
GIST-T1, mean = 1.5, S.E. = 1.1 versus control, mean = 17.4,
S.E. = 5.1, P < 0.001; Fig. 4).
The VLA-4-specific inhibitors had a similar effect to GIST cell inva-
sion as ITGA4-specific siRNAs. The number of invaded cells
decreased in each GIST cell line after VLA-4 inhibitor treatments.
However, only BIO1211 decreased the numbers of invaded cells sta-
tistically significantly in the GIST882 and GIST-T1 cell lines (Fig. 5).
Discussion
We found that (i) ITGA4 is highly expressed in GISTs, (ii) decreased
ITGA4 signalling blocks GIST cell invasion in vitro, (iii) ITGA4 protein
expression is associated with some adverse prognostic features in
GIST such as a high mitotic count, presence of tumour necrosis and
metastatic disease and (iv) GIST ITGA4 protein expression is associ-
ated with unfavourable survival outcome. Somewhat unexpectedly,
ITGA4 expression was associated also with gastric location of GIST in
the present series, although patients with gastric GIST have, in gen-
eral, more favourable survival as compared with patients with non-
gastric GIST [31]. Little is known about the importance of ITGA4 and
Fig. 2 Associations between GIST ITGA4
protein expression with overall survival
(A) and GIST-specific survival (B). The
patients censored are indicated with a bar.
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other integrins in GIST pathogenesis, but since integrins mediate a
wide variety of cellular effects and signalling that can result in tumour
progression and metastasis in various types of human cancer [12], it
may not be unexpected that integrins are important also in the molec-
ular pathogenesis of GISTs.
To our knowledge, the observations that ITGA4 expression in
GISTs is linked with factors such as presence of tumour necrosis,
high mitotic counts and poor survival are novel, and they appear to
be in line with the reported role of a4 integrins in the embryonal
development, normal tissues and in cancer. The a4 integrins are
expressed during haematopoiesis on early pluripotent progenitor
cells, mononuclear leucocytes and eosinophils [32]. In cells such as
the myocytes and placental and fibroblastic cells, a4 integrin expres-
sion is highly dependent on the developmental stage and growth
stimuli [20]. a4 integrins have an important role in leucocyte traffick-
ing, and they are involved in the pathogenesis of several chronic
diseases including multiple sclerosis, contact hypersensitivity,
rheumatoid arthritis and inflammatory bowel diseases [33–35]. ITGA4
expression has been found to be associated with poor prognosis in a
few cancer types including neuroblastoma and chronic lymphocytic
leukaemia [36–38]. Interaction between ITGA4 in melanoma cells and
VCAM-1 on activated endothelial cells enhances the metastatic capac-
ity of melanoma cells [39], and inhibition of ITGA4 in MV3 melanoma
cells with non-anticoagulant heparin derivatives attenuates melanoma
metastatic potential [40]. Interestingly, leiomyosarcomas had a simi-
lar ITGA4 expression pattern as GISTs. The reasons for this remain
speculative.
Besides cell migration and invasion, ITGA4 may also influence cell
proliferation. In myeloid cells, ITGA4 activation leads to tumour
Fig. 3 A Western plot showing expression of ITGA4, KIT and actin (con-
trol) in the GIST882, GIST48 and GIST-T1 cell lines. Expression 72 hrs
after KIT and ITGA4 siRNA transfection are shown.
Fig. 4 Effect of transfection with control
siRNA, KIT siRNA and ITGA4 siRNA on
cell proliferation and invasion in GIST882
(A, B), GIST48 (C, D) and GIST-T1 (E, F)
cell lines. Panels (A, C, E): cell proliferation
decreased with KIT siRNA transfection in
each cell line, whereas ITGA4 siRNA trans-
fection had no effect; *P < 0.01. Panels
(B, D, F): ITGA4 siRNA transfection
decreased cell invasion of all cell lines 24 hrs
(GIST882 and GIST48) or 96 hrs (GIST-T1)
after transfection. The bars indicate the aver-
age number of invaded cells (the standard
errors per one microscope field are shown).
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inflammation and growth, whereas natalizumab, a recombinant
humanized anti-ITGA4 antibody, decreases myeloma growth by
blocking the interaction between myeloma cells and bone marrow
stromal cells [41]. We found a positive association between GIST
ITGA4 expression and a high tumour mitotic count in a large GIST
patient series, but knock-down of ITGA4 expression did not influence
cell proliferation in GIST cell lines. Tumour ITGA4 expression was
associated with poor overall and GIST-specific survival, and down-
regulation of ITGA4 mRNA expression or VLA-4 inhibition in cell lines
decreased dramatically the invasion activity of GIST cells, suggesting
that the major role of ITGA4 in GIST progression is the promotion of
tumour invasion and dissemination rather than cell proliferation.
The study has some limitations. Stratifying ITGA4 protein expres-
sion based on immunohistochemistry is subjective, but the immuno-
histochemistry scoring correlated with tumour ITGA4 mRNA qPCR
measurements in a subset of cases, and showed associations with
clinical parameters in a large clinical GIST series, suggesting that the
scoring of the ITGA4 immunostainings reflected the sample ITGA4
content. The somewhat differing proportions of ITGA4-positive GISTs
found in the two series investigated (78.6% and 42.2%) may be due
to a higher proportion of low-risk GISTs in the population-based
western Sweden series, but we cannot exclude the effect of factors
that may influence ITGA4 immunostaining, such as differences in
tissue sample fixation. Conformation of the current findings in further
GIST series is warranted. Study of gene silencing in more than three
GIST cell lines could have improved the robustness of the findings,
but, to our knowledge, only few GIST cell lines are generally available.
In summary, ITGA4 is highly expressed in GISTs as compared
with most other human tumour types and most normal tissues.
ITGA4 may promote invasiveness of GIST, and GIST ITGA4 protein
expression is associated with presence of metastases. Tumour ITGA4
expression was also associated with the high-risk category of the NIH
classification and with poor GIST-specific and overall survival. The
present results suggest that ITGA4 is an important integrin in the
molecular pathogenesis of GIST and may influence their clinical beha-
viour. The findings suggest that agents that target ITGA4 may warrant
testing in the treatment of GIST.
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